WO2000076455A2 - Chicken growth hormone releasing hormone receptor - Google Patents
Chicken growth hormone releasing hormone receptor Download PDFInfo
- Publication number
- WO2000076455A2 WO2000076455A2 PCT/US2000/016135 US0016135W WO0076455A2 WO 2000076455 A2 WO2000076455 A2 WO 2000076455A2 US 0016135 W US0016135 W US 0016135W WO 0076455 A2 WO0076455 A2 WO 0076455A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ghrh
- chicken
- receptor
- seq
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention is directed to chicken growth hormone releasing hormone GHRH receptor, ligands that bind to the GHRH receptor, and nucleic acid sequences encoding the GHRH receptor.
- Growth hormone releasing hormone is a hypothalamic hormone that acts at a pituitary receptor to stimulate the pulsatile release of GH.
- GH is required for normal growth and development in the young, and has continuing importance in adults affecting such diverse functions as muscle maintenance, fat deposition, skin thickness, wound healing and exercise performance.
- GHRH also has direct effects on sleep. These actions have widespread clinical implications not only when considering GH deficiency syndromes, but also the sharply diminished GH levels that occur with aging and obesity.
- the anabolic and anticatabolic activities of GH have also recently been shown to ameliorate the muscle wasting and weight loss seen with AIDS.
- GHRH and other regulators of the GH axis also have great potential in agricultural applications because they can stimulate growth and improve the efficiency of feed utilization. They control the relative partitioning of nutrients between muscle and fat and so may allow the production of leaner livestock and higher yields of milk, hair and feathers.
- GHRH thyroid releasing hormone
- GnRH gonadotropin releasing hormone
- Research studies have been inconclusive as to the physiological role of GHRH in birds.
- a putative chicken GHRH polypeptide has been cloned and synthesized but found to have little or no GH releasing activity at chicken pituitary cells or in live chickens. Despite this, chicken pituitaries and live chickens do respond to mammalian GHRH with GH release.
- Studies in chickens using mammalian GHRH have not been successful in improving growth. Thus, it has been speculated that chickens have no functional GHRH receptor.
- GHRH-R GHRH receptor
- the chicken GHRH receptor has been cloned and functions similar to the natural source tissue (chicken pituitary cells) in that it responding to human GHRH but not to the reported chicken hormone. This led us to suspect a problem with the supposed chicken GHRH hormone.
- the chicken GHRH polypeptide was then recloned from freshly flash frozen chicken hypothalami and sequenced. The nucleic acid sequence of the newly isolated chicken GHRH gene did not agree with the published sequence and the synthesized chicken hormone based on this new sequence was found to be active at the cloned chicken GHRH receptor.
- the present invention is directed to the use of the new chicken GHRH hormone and its corresponding GHRH receptor to enhance the production of larger, leaner chickens and other avian species used for meat production.
- Fig. 1 A and IB is a graph showing the binding activity of the reported chicken GHRH (Fig. 1A) and the present chicken GHRH (Fig. IB) at the recombinant chicken GHRH receptor. Binding at recombinant chicken GHRH receptor is competed by the new chicken polypeptide (Fig IB) but not by the published polypeptide (Fig 1 A).
- Figs. 2A and 2B is a graph showing cAMP signaling through the recombinant chicken GHRH receptor.
- Fig. 2A shows that the published polypeptide is inactive in stimulating second messenger signaling at the cloned chicken GHRH receptor, while Fig. 2B shows that the cloned chicken GHRH polypeptide reported herein is active.
- Fig. 3 Binding activity at chicken pituitary membranes, showing that the new polypeptide sequence is active at the endogenous receptor in chicken pituitaries.
- nucleic acid As used herein, “nucleic acid,” “DNA,” and similar terms also include nucleic acid analogs, i.e. analogs having other than a phosphodiester backbone.
- nucleic acid analogs i.e. analogs having other than a phosphodiester backbone.
- peptide nucleic acids which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention.
- nucleic acid encompasses RNA as well as single and double-stranded DNA and cDNA.
- peptide encompasses a sequence of 3 or more but less than 16 amino acids wherein the amino acids are naturally occurring or synthetic (non-naturally occurring) amino acids.
- polypeptide as used herein is a sequence of 16 or more amino acids wherein the amino acids are naturally occurring or synthetic (non-naturally occurring) amino acids.
- Peptide or polypeptide mimetics include peptides or polypeptides having one or more of the following modifications: 1. sequences wherein one or more of the peptidyl — C(O)NR— linkages (bonds) have been replaced by a non-peptidyl linkage such as a ⁇ CH2-Carbamate linkage
- Naturally occurring amino acid residues in peptides/polypeptides are abbreviated as recommended by the IUPAC-IUB Biochemical Nomenclature Commission as follows: Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is He or I; Methionine is Met or M; Norleucine is Nle; Valine is Vat or V; Serine is Ser or S; Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyr or Y; Histidine is His or H; Glutamine is Gin or Q; Asparagine is Ash or N; Lysine is Lys or K; Aspartic Acid is Asp or D; Glutamic Acid is Glu or E; Cysteine is Cys or C; Tryptophan is Trp or W; Arginine is Arg or R; Glycine is Gly or G, and X is any amino acid.
- Naturally occurring amino acids include, by way of example, 4-hydroxyproline, 5-hydroxylysine, and the like.
- Synthetic or non-naturally occurring amino acids refer to amino acids which do not naturally occur in vivo but which, nevertheless, can be incorporated into the peptide/polypeptide structures described herein.
- the resulting "synthetic peptide" contain amino acids other than the 20 naturally occurring, genetically encoded amino acids at one, two, or more positions of the peptides. For instance, naphthylalanine can be substituted for trytophan to facilitate synthesis.
- Other synthetic amino acids that can be substituted into peptides include L-hydroxypropyl,
- L-3,4-dihydroxyphenylalanyl alpha-amino acids such as L-alpha-hydroxylysyl and D-alpha-methylalanyl, L-alpha.-methylalanyl, beta.-amino acids, and isoquinolyl.
- D amino acids and non-naturally occurring synthetic amino acids can also be incorporated into the peptides.
- Other derivatives include replacement of the naturally occurring side chains of the 20 genetically encoded amino acids (or any L or D amino acid) with other side chains.
- the term "pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
- biologically active fragments of the GHRH receptor encompasses natural or synthetic portions of the full-length receptor which are capable of binding a receptor-specific ligand (i.e. GHRH polypeptide), or which are capable of eliciting in a host animal GHRH-R specific antisera or a second messenger response while either conjugated to a carrier or in nonconjugated form.
- a receptor-specific ligand i.e. GHRH polypeptide
- GHRH growth hormone releasing hormone
- the GHRH receptor is a member of family B of the seven transmembrane, G-protein coupled receptors.
- GHRH polypeptides from mammals and fish stimulate GH release from the pituitary in vivo and in vitro suggesting the presence of GHRH like receptors on the chicken somatotropes, however, the recently cloned and synthesized chicken GHRH is a very poor GH secretagogue.
- a specific GHRH receptor has not been characterized in the chicken, raising questions about the regulation of GH secretion. A zoo blot probed with a lkb fragment of human GHRH receptor DNA failed to elicit a signal in the chicken. This raises questions about the regulation of GH secretion in the chicken.
- the chicken GHRH has now been isolated and used to identify a new chicken GHRH that is capable of activating the chicken GHRH receptor.
- the identification of the chicken GHRH receptor implies that GH secretion is under the control of regulatory mechanisms similar to those in mammals and will allow more detailed study of this endocrine system in chickens. It will also contribute to structure/function studies of how the GHRH receptor works by indicating receptor domains that are required to be conserved and those that are important for ligand specificity.
- the chicken GHRH receptor will also be used in accordance with the present invention to identify GHRH analogs and mimetics that stimulate GH release in poultry. This will have great use agriculturally for the improvement of feed utilization and the efficient production of larger, leaner chickens and other commercially viable avian species.
- the present invention is directed to the use of the chicken GHRH polypeptide and the chicken GHRH receptor to enhance the production of larger, leaner chickens and other avian species used for meat production and enhance feed utilization.
- a chicken GHRH polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or a polypeptide that differs from SEQ ID NO: B by one or more conservative amino acid substitutions yet retains its ability to stimulating second messenger signaling at the cloned chicken GHRH receptor, is administered to an agriculturally significant avian species to enhance the growth of the avian species.
- the sequence of a chicken GHRH polypeptide has been previously reported however that polypeptide has been tested in chickens and chicken pituitary cells, and had little or no GH releasing activity while human GHRH was found to be active.
- the present invention is directed to GHRH polypeptides that are capable of stimulating second messenger signaling at the chicken GHRH receptor comprising the sequence of SEQ ID NO: 4.
- the sequence of the chicken GHRH gene, with the 5' and 3' untranslated region (start codon located at bp 54, stop codon located at bp 1312) is shown as SEQ ID NO: 1.
- the coding sequence of chicken GHRH is shown as SEQ ID NO: 6.
- a chicken GHRH having the amino acid sequence of SEQ ID NO: 2 is provided. This sequence differs from the previously reported sequence at amino acid number 21, wherein the present sequence has a lysine and the previously reported sequence has an asparagine.
- Synthesis of the chicken GHRH(1-33)NH 2 based on the nucleotide sequence of SEQ ID NO: 1 , produced a polypeptide that is active in binding to chicken pituitary membranes and competes with human GHRH.
- the new polypeptide is active in binding and in signaling through the second messenger cAMP. This new chicken polypeptide is thus a functional GHRH.
- While the new sequence is active, it is less potent at the chicken receptor than human GHRH. This may be inherent to chicken physiology, or it may be an artifact of the truncated polypeptide (1-33) was tested. Only amino acids 1-29 are required for full GHRH activity in mammalian systems that have been tested. This may be different in other animals. Active fragments of the chicken GHRH are also within the scope of this invention, including but not limited to truncated polypeptides that include amino acid residues 1-33 and 1-29 of SEQ ID NO: 2, respectively. Thus, one aspect of the present invention relates to a substantially pure protein and biologically active fragments thereof having chicken growth hormone releasing hormone (GHRH) receptor activity.
- GHRH chicken growth hormone releasing hormone
- the present invention also encompasses nucleic acid sequences that encode a peptide or polypeptide that binds to chicken GHRH receptor and is capable of signaling through the second messenger cAMP is provided.
- the nucleic acid comprises the sequence of SEQ ID NO: 6.
- a transgenic avian species is provided wherein one or more of the chickens cells comprise a nucleic acid sequence encoding the chicken GHRH protein of SEQ ID NO: 2. Accordingly, the present invention provides for recombinant organisms and progeny thereof comprising an exogenous gene encoding for a chicken GHRH and biologically active fragments thereof.
- the present invention is also directed to pharmaceutical formulations comprising the chicken GHRH polypeptide for administration to avian species (preferably to chickens) wherein the GHRH polypeptide interacts with the chicken GHRH receptor and produces a signal through a secondary messenger molecule.
- the chicken GHRH polypeptide compositions are administered to chickens to enhance feed utilization and enhance the growth and production of lean muscle mass in an avian species.
- the administered GHRH polypeptide comprises the amino acid sequence of SEQ ID NO: 2.
- the present invention is also directed to the GHRH receptor (GHRH-
- the present invention provides the amino acid sequences of chicken GHRH-R and biologically active fragments thereof, as well as oligonucleotide probes or primers which can hybridize to a gene encoding chicken GHRH-R or fragments thereof.
- the invention provides for an isolated nucleic acid sequence encoding a GHRH receptor, recombinant vectors including said sequence and host cells containing said sequence useful in production of a GHRH-receptor or biologically active fragments thereof (including proteins and polypeptides having GHRH-R activity).
- a gene encoding for a protein or polypeptide having chicken GHRH-R activity is isolated and connected with a vector DNA to form a recombinant DNA; the vector DNA including said gene is capable of replicating in a prokaryotic or eukaryotic cell.
- the gene encoding for a protein or polypeptide having chicken GHRH-R activity is located downstream of a promoter in the vector, and is replicated as part of the vector.
- the recombinant DNA is then incorporated into a host cell, which did not previously contain said gene, to form a transformed or transected cell line capable of expressing chicken GHRH-R or biologically active fragments thereof.
- the present invention also provides for recombinant organisms and progeny thereof comprising an exogenous gene encoding for a chicken GHRH-R and biologically active fragments thereof.
- the invention is also directed to pharmaceutical compositions comprising an effective amount of the pure receptor or fragments thereof, or proteins and polypeptides having chicken GHRH-R activity in combination with a pharmaceutically acceptable carrier, and provides a method for the therapeutic use of such pharmaceutical compositions.
- the receptor and receptor fragments proteins and polypeptides having chicken GHRH-R ligand binding or immunological activity
- GHRH-R is attached to an inert substrate (such as a polymer bead) using standard techniques known to the skilled practitioner. Such bound material can be contacted with a solution of potential GHRH analogs under conditions that allow binding.
- a purified nucleic acid sequence is provided that encodes for the chicken growth hormone releasing hormone receptor or biologically active fragments thereof.
- a vector comprising a nucleic acid sequence encoding a chicken GHRH polypeptide or chicken GHRH receptor, or biologically active fragments thereof, is provided.
- the vector is an expression vector that is operably linked to nucleic acid sequences that encode the GHRH polypeptide or the GHRH receptor.
- Such recombinant expression vectors can be used to transform cells to produce a host cell or living cell line comprising a nucleic acid sequence encoding a growth hormone releasing hormone receptor or biologically active fragment thereof.
- a transgenic avian species is produced (preferably a chicken) wherein the avian species comprises one or more cells that express exogenously introduced recombinant GHRH polypeptide or the GHRH receptor.
- It is a further object of the present invention to provide a pharmaceutical composition comprising the GHRH polypeptide of SEQ ID NO: 2, or biologically active fragment thereof, and a therapeutic method for administering an effective amount of same to an organism to bind to endogenous GHRH receptor.
- a pharmaceutical composition comprising the GHRH polypeptide of SEQ ID NO: 2, or biologically active fragment thereof, and a therapeutic method for administering an effective amount of same to an organism to bind to endogenous GHRH receptor.
- screening assays which utilize chicken GHRH-R or biologically active fragments thereof for testing compounds which may interact with chicken GHRH-R or fragments thereof.
- such compounds will have physiological properties that allow the compounds to be administered orally.
- the isolated chicken GHRH receptor is also useful in raising GHRH-R specific antibodies. Such antibodies may, by blocking the receptor site, effectively prevent GHRH binding and thereby block growth. Other antibodies can be used to activate the GHRH-R receptor (e.g., thyroid stimulating antibodies, such as those causing Graves Disease). Accordingly, the chicken GHRH-R, or an immunogenic portion thereof can be used to elicit antibodies which bind to the receptor and thereby induce or block activity. In accordance with one embodiment, the antigenic peptide fragment of SEQ ID NO: 5 is used to elicit antibody production. Pharmaceutical compositions containing the receptor or segment fragments can be used to treat disorders resulting from or associated with an excess of circulating GHRH. Such compositions can be employed for in vivo administration to bind circulating GHRH, thus preventing its binding to endogenous receptor.
- extracellular loop fragments particularly those not containing N- glycosylation sites (carbohydrate may sterically interfere with antibody binding) are preferred.
- intracellular loops are also useful in production of antibodies which may be used for solid phase binding of the receptor protein in screening and other assays.
- a recent study of antibodies directed against the three EC loops of the thyrotropin receptor indicates a heterogeneity in their biological activities, including the induction of blocking antibodies using the EC-3 Loop as the antigen. See Ohmori, M., et al., Biochem. Biophys. Res. Comm., 174:399 (1991). Therefore, a broad panel of anti-polypeptide and anti-receptor antibodies is prepared and carefully evaluated in order to determine the epitopes required for the induction of blocking or activating antibodies.
- polypeptides are produced by conventional solid phase synthesis cleaved by HF, and HPLC purified (van Regenmortal, M. H., In Synthetic Polypeptides as Antigens, Elsevier, New York, pages 41-93 (1988). Polypeptides are then typically coupled to a carrier immunogen such as keyhole limpet haemocyanin (KLH) or ovalbumin via glutaraldehyde by conventional procedures, and these conjugates used to immunize mice and rabbits.
- KLH keyhole limpet haemocyanin
- the specificity of the antibodies is also evaluated by the technique of Western Blotting. See Towbin, It. et al., PNAS USA, 76:4350 (1979). Specific antibodies reorganize a 55 kDa protein in crude membrane preparations, in WGA eluted glycoproteins, or in streptavidin eluates. Membranes from a cell line devoid of receptor serve as a negative control. This procedure also gives information about the degree of cross-reactivity of the antibodies with receptor subtypes from other cell lines and tissues (brain, pituitary) and obviates the need for receptor purification from each source. It is beneficial to obtain both tissue-specific antibodies for physiological studies and cross-reactive antibodies for possible use in purification of the receptor from various tissues using immunoaffinity chromatography.
- Monoclonal antibodies to the GHRH receptor are prepared using conventional methods. See Harlow, H., and Lane, D., In Antibodies: A Laboratory Manual, Cold Spring Harbor Lab, New York, pages 139-240 (1988).
- the antigens used for immunization include (1) KLH-polypeptide conjugates corresponding to the extracellular regions as described above, (2) purified receptor from chicken anterior pituitary membranes, (3) purified receptor deglycosylated with neuraminidase or N- glycosidase and repurified by SDS-PAGE and electro-elution, (4) receptor purified from recombinant sources, such as transected CHO cells, or baculovirus tested for reactivity to the polypeptide immunogen by ELIS A or protein immunogen by Western blot.
- hybridomas Those which display circulating antibodies to the receptor or its polypeptides are utilized for the preparation of hybridomas. Briefly, spleen cells are removed and fused in the presence of polyethylene glycol to SP2/D myeloma cells that are deficient in the enzyme hypoxanthine-guanine phosphoribosyl aminopterine-thymidine, which selects for true hybrids of both cell types since spleen cells do not grow in culture. Hybridoma supernates are screened for antibody to the receptor by (1) Western blots of purified receptor or WGA-eluted glycoproteins, (2) ELISA using inhibition of radiolabelled ligand binding to membranes. Those hybridomas which are positive are propagated and recloned by limiting dilution or growth in soft agar; this ensures their monoclonal nature. Positive clones are used to induce tumors in mice and accumulate the antibody in ascites fluid.
- Both polyclonal and monoclonal IgG antibodies are purified by conventional ammonium sulfate precipitation and Protein A chromatography. See Harlow, supra. Antibodies are analyzed for their ability to block or activate radioligand binding to membranes in the standard binding assay described above. Those antibodies that show promise for ligand blocking or activation are tested in vivo using for example a rat model, e.g., by using indwelling venous catheters on rats in order to monitor GH levels after administration of anti-GHRH receptor antibody. See Miell, J., et al., J. Endocrinol, 131 :75 (1991).
- Those antibodies which show the most in vivo activity at this point are examined to define their epitopes (if not already determined) on the receptor. Those epitopes represent antigenic fragments of the receptor which when used as immunogens induce antibodies possessing the desired physiological effect of altering levels of GH production.
- RT-PCR with nested PCR primers was used to amplify the full coding region of the chicken GHRH polypeptide.
- the hypothalami from 10 chickens were snap frozen within two minutes of death and stored at -70° C.
- RNA was extracted from the hypothalami using TriReagent.
- the RNA was used in a reverse transcriptase (Superscript) reaction prior to a polymerase chain reaction (Taq polymerase).
- the PCR products were purified by agarose gel electrophoresis and a Quiagen affinity column and then cloned into the pTarget vector (Promega) using T 4 ligase overnight at 15 ° C.
- the ligation reactions used to transform E. coli (JM109) were selected and screened by PCR to identify clones containing the GHRH cDNA.
- the resultant cDNA sequence for the HGRH receptor is shown in SEQ ID NO: , and the encoded polypeptide in SEQ ID NO: . (figures 3 & 4).
- the chicken cDNA sequence has less than 63% identity with the human GHRH receptor compared to 83 to 96% identity among known mammalian GHRH receptors.
- Fig. 1 A and IB present the data from a competition experiment.
- the data show chicken GHRH polypeptide (asparagine 21 ) [(cGHRH(Asp 21 )] failed to compete with hGHRH (Fig. 1A) whereas chicken GHRH polypeptide (lysine 21 ) [(cGHRH(Lys 21 )] did compete with hGHRH (Fig. IB) for binding to the cGHRH receptor.
- FIGS. 2 A and 2B show the results of GHRH mediated cAMP stimulation in HEK293 cells expressing the cGHRH receptor. Cells lacking the cGHRH receptor (HEK293) were used as the control. The data show cGHRH(Asp 21 ) is inactive in stimulating second messenger signaling at the cloned chicken GHRH receptor (Fig 2A), while Fig 2B shows that (cGHRH(Lys 21 ) is active.
- the chicken GHRH-R can be used to increase growth in domestic livestock, as well as improve immune functions, appetite control, feed efficiency and nutrition.
- Initial attempts using an available chicken pituitary cDNA library failed because the abundance of receptor message was too low.
- the available chicken pituitary libraries did not have sufficient complexity to include such rare messages.
- the chicken (Gallus gallus) GHRH receptor sequence is used to map the binding site of GHRH on its receptor.
- Mapping of the site is conducted using a series of photoaffmity crosslinking probes followed by analysis of protease cleavage maps. The differences between different species allows the identification of functional sites within receptor domains. Characterizing the binding site will lead to the development of GHRH analogs and mimetics that provide pharmacological means to alter GH release.
- the chicken GHRH receptor will also be used to identify GHRH analogs and mimetics that stimulate GH release in poultry.
- the nucleic acid sequence of SEQ ID NO: or SEQ ID NO: is used as a probe to isolate related genes from chicken and other avian species. This could be important agriculturally for the improvement of feed utilization and the efficient production of larger, leaner chickens and other avian species used for meat production.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/009,643 US7078514B1 (en) | 1999-06-12 | 2000-06-12 | Chicken growth hormone releasing hormone receptor |
AU54834/00A AU5483400A (en) | 1999-06-12 | 2000-06-12 | Chicken growth hormone releasing hormone receptor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13876899P | 1999-06-12 | 1999-06-12 | |
US60/138,768 | 1999-06-12 | ||
US17638700P | 2000-01-14 | 2000-01-14 | |
US60/176,387 | 2000-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000076455A2 true WO2000076455A2 (en) | 2000-12-21 |
WO2000076455A3 WO2000076455A3 (en) | 2001-04-05 |
Family
ID=26836531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/016135 WO2000076455A2 (en) | 1999-06-12 | 2000-06-12 | Chicken growth hormone releasing hormone receptor |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5483400A (en) |
WO (1) | WO2000076455A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994000482A1 (en) * | 1992-06-23 | 1994-01-06 | Thorner Michael O | Isolation and characterization of the growth hormone releasing hormone receptor |
US5695954A (en) * | 1993-05-14 | 1997-12-09 | University Of Victoria Innovation & Development Corporation | DNA encoding two fish neuropeptides |
WO1998032857A1 (en) * | 1997-01-23 | 1998-07-30 | University Of Victoria Innovation And Development Corporation | Chicken neuropeptide gene useful for poultry production |
-
2000
- 2000-06-12 AU AU54834/00A patent/AU5483400A/en not_active Abandoned
- 2000-06-12 WO PCT/US2000/016135 patent/WO2000076455A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994000482A1 (en) * | 1992-06-23 | 1994-01-06 | Thorner Michael O | Isolation and characterization of the growth hormone releasing hormone receptor |
US5695954A (en) * | 1993-05-14 | 1997-12-09 | University Of Victoria Innovation & Development Corporation | DNA encoding two fish neuropeptides |
WO1998032857A1 (en) * | 1997-01-23 | 1998-07-30 | University Of Victoria Innovation And Development Corporation | Chicken neuropeptide gene useful for poultry production |
Non-Patent Citations (2)
Title |
---|
MCRORY ET AL.: 'Expression and alternative processing of a chicken gene encoding both growth hormone-releasing hormone and pituitary adenylate cyclase-activating polypeptide' DNA AND CELL BIOLOGY vol. 16, no. 1, January 1997, pages 95 - 102, XP002931062 * |
PORTER ET AL.: 'Ontogeny of growth hormone (GH)-secreting cells during chicken embryonic development: Initial somatotrophs are responsive to GH-releasing hormone' ENDOCRINOLOGY vol. 136, no. 5, May 1995, pages 1850 - 1856, XP002931082 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000076455A3 (en) | 2001-04-05 |
AU5483400A (en) | 2001-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Richardson et al. | Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome reaction | |
US20090162367A1 (en) | Nucleotide and protein sequences of Nogo genes and methods based thereon | |
AU656144B2 (en) | Histidine substituted growth hormone releasing factor analogs | |
US7273929B2 (en) | B1k chain of laminin and methods of use | |
Nicholson et al. | Monoclonal antibodies to the human TSH receptor: epitope mapping and binding to the native receptor on the basolateral plasma membrane of thyroid follicular cells | |
US7649084B2 (en) | Recombinant glycoproteins related to feline thyrotropin | |
US20070161545A1 (en) | Triple polypeptide complexes | |
CA1330420C (en) | Compositions containing growth hormone peptide fragments | |
US5472856A (en) | Recombinant human thymopoietin proteins and uses therefor | |
AU674881B2 (en) | Growth hormone potentiating molecules | |
US7078514B1 (en) | Chicken growth hormone releasing hormone receptor | |
US20030166561A1 (en) | Peptide | |
WO2000076455A2 (en) | Chicken growth hormone releasing hormone receptor | |
CA2536146A1 (en) | Splice variants of erbb ligands, compositions and uses thereof | |
US20030050434A1 (en) | Peptide | |
US7544485B2 (en) | Baldness related gene and the polypeptide encoded thereby, and uses | |
EP0668873A1 (en) | Antagonists of human gamma interferon | |
WO1994009765A1 (en) | Functional interactions between glial s-100b and central nervous system serotonergic neurons | |
WO2001004298A1 (en) | Novel physiologically active substance, process for producing the same and use thereof | |
CAHILL et al. | Recognition of porcine growth hormone by a panel of monoclonal antibodies | |
WO1996030405A1 (en) | Peptides with growth promotion properties | |
CS272790A2 (en) | Peptides with biological effect | |
CN1408866A (en) | Human fertilization promoting peptide receptor TCP11 and its coding sequence, preparation and use | |
JP2000157273A (en) | New physiologically active peptide and its use | |
EP0731836A1 (en) | Chicken oocyte receptor p95 (vldl/vtg receptor) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10009643 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |